George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- May 15 2003
- Volume 10
- Issue 9
JACKSON TURNS BLUE
Author(s)Michael Sheehan
Advertisement
For the first time in modern history,the nation's currency will featurea color other than green. The$20 bill, which was unveiled in lateMarch and will be in circulation byautumn, will contain 2 colors, oneof which will be a subtle backgroundhue, and the other used toprint the seals, numerals, and otheritems that normally appear on thebill. The new anticounterfeitingstrategy is aimed at crooks who uselaser printers and scanners to pumpout funny money. About 40% of thebogus cash that was seized last yearwas made with laser printers, withthe $20 bill ranking as the mostpopular target for counterfeiters.The $50 bill is next up for revamping,followed by the $100 bill.
Articles in this issue
about 18 years ago
Postwar Economy Refocuses Attentionabout 18 years ago
Model Portfolio Series: Conservative Growthabout 18 years ago
How Does Your Financial IQ Measure Up?about 18 years ago
History Provides Lessons in Investingabout 18 years ago
Read the Market's Long-Term Performanceabout 18 years ago
Less Is More When Buying Stock Spinoffsabout 18 years ago
Weigh the Aspects of Variable Annuitiesabout 18 years ago
Maximize Your Sale of Stocks at a Lossabout 18 years ago
Realize the Importance of Market Timingabout 18 years ago
Speed Through Annual Reports Like a ProAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5